Cue Biopharma vs Nanobiotix
Nanobiotix is the larger business, with $36.9m of revenue in fiscal 2025 against $27.5m for Cue Biopharma (1.3 times as much). Cue Biopharma grew faster (195.7% against -573.6%). Nanobiotix kept more of each dollar of sales as profit: a net margin of -73.5% against -96.9%.
| Latest fiscal year | Cue BiopharmaCUE, 2025 | NanobiotixNBTX, 2025 |
|---|---|---|
| Revenue | $27.5m | $36.9m |
| Revenue growth | 195.7% | -573.6% |
| Net income | −$26.6m | −$27.1m |
| Operating margin | — | -33.2% |
| Net margin | -96.9% | -73.5% |
| Return on equity | -121.1% | — |
| Free cash flow | −$21.9m | −$38.4m |
| Cash | $27.1m | $61.9m |
| Total debt | — | $0 |
| Debt to equity | — | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 29 | — |
| Market value | $106m | $1.37bn |
| Price vs our value range | — | — |
| Moat score | 8 (Weak) | — |
| Insider trades, 12 months | 5 buys, 15 sales | 0 buys, 0 sales |